SCHEMBL16446446

SCHEMBL16446446

COC(=O)c1ccc(-n2ccc3c(C)nc(-c4ccc(F)c(F)c4)nc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 4/20 0.50
▸ PIK3CD O00329 1/20 0.41
▸ PIK3CA P42336 1/20 0.41
▸ MTOR P42345 1/20 0.41
▸ PTK2 Q05397 1/20 0.40
▸ ERN1 O75460 1/20 0.40
▸ ADORA2A P29274 1/20 0.38
▸ ADORA2B P29275 1/20 0.38
▸ RXRA P19793 1/20 0.38
▸ HPGD P15428 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ MAP2K4 P45985 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ NFKB1 P19838 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ NFKB2 Q00653 1/20 0.36
▸ RELA Q04206 1/20 0.36
▸ ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16446770 0.91 PDE4B (0.59) PDE4BPIK3CDPIK3CAMTORPTK2
SCHEMBL16445876 0.83 PDE4B (0.68) PDE4BPTK2MAPTNPC1RAB9A
SCHEMBL16447006 0.82 PDE4B (0.64) PDE4BPIK3CAPTK2RXRARAB9A
SCHEMBL16447005 0.82 PDE4B (0.64) PDE4BPIK3CAPTK2RXRARAB9A
SCHEMBL16446537 0.78 ALDH1A1 (0.43) PDE4BPTK2ADORA2AADORA2BMAPT
SCHEMBL16446539 0.75 PDE4B (0.40) PDE4BPTK2ADORA2AADORA2BHPGD
SCHEMBL16446612 0.73 PDE4B (0.84) PDE4BPTK2MAPTNPC1RAB9A
SCHEMBL16446725 0.72 PTK2 (0.39) PDE4BPTK2ADORA2AADORA2BMAPT
SCHEMBL4652494 0.71 ERN1 (0.64) ERN1MAPTMAP2K4NPC1RAB9A
SCHEMBL16448282 0.69 PDE4B (0.64) PDE4BPTK2RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030565-B1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS GRUENENTHAL GMBH (DE) 2017-07-19 — — EP disclosed
US-9688683-B2 Substituted condensed pyrimidine compounds Grünenthal GmbH (DE) 2017-06-27 — — US disclosed
EP-3030565-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-15 — — EP disclosed
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-02 — — US disclosed
WO-2015018534-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2015-02-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS PDE4A, PDE4B, TYMP PDE4B 2/4885PIK3CD 946/4885PIK3CA 522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback